AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinson’s Disease Diagnostic Imaging Agent
Over the last four years,
Prof.
The program has generated multiple compounds that bind with high-affinity and selectivity to human PD brain-derived, pathological a-syn in preclinical studies. A lead a-syn PET tracer candidate entered clinical trials earlier this year — also with MJFF funding — focused on imaging of pathological a-syn in PD and other synucleinopathies. AC Immune’s a-syn PET tracers are derived from the Company’s proprietary small molecule MorphomerTM discovery platform. The Company is also advancing the development of oral small molecule a-syn inhibitors and SupraAntigenTM-derived anti-a-syn antibodies as novel therapeutic candidates targeting PD and a-syn-related NeuroOrphan diseases.
Dr.
About
As a strategic leader in the field of neurodegenerative diseases,
For further information, please contact:
U.S. Investors Joshua Drumm, Ph.D. AC Immune Investor Relations Phone: +1 646 876 5538 E-mail: joshua.drumm@acimmune.com |
U.S. Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 E-mail: kgallagher@lavoiehealthscience.com |
European Media Judith Moore AC Immune Global Communication Lead Phone: +44 7932 053829 Email: judith.moore@acimmune.com |
European Investors Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 E-mail: chris@lifesciadvisors.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA